SCHEMBL6310219

SCHEMBL6310219

COc1ccc(OC)c(S(=O)(=O)N[C@@H]2CCC[C@H]2N2CCC(Cc3ccc(Cl)cc3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRHBP P24387 3/20 0.51
▸ CRHR2 Q13324 3/20 0.51
▸ KMT2A Q03164 2/20 0.49
▸ CCR3 P51677 2/20 0.49
▸ CCR5 P51681 1/20 0.49
▸ POLB P06746 1/20 0.46
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ CTSS P25774 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ CTSC P53634 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ TSHR P16473 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MCOLN3 Q8TDD5 2/20 0.42
▸ MCOLN2 Q8IZK6 1/20 0.42
▸ MCOLN1 Q9GZU1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6310216 1.00 CRHBP (0.51) CRHBPCRHR2KMT2ACCR3CCR5
SCHEMBL6307794 0.85 CRHBP (0.55) CRHBPCRHR2KMT2AALDH1A1TP53
SCHEMBL6307792 0.85 CRHBP (0.55) CRHBPCRHR2KMT2AALDH1A1TP53
SCHEMBL6305460 0.85 CRHBP (0.54) CRHBPCRHR2KMT2ACCR3MCOLN3
SCHEMBL6305458 0.85 CRHBP (0.54) CRHBPCRHR2KMT2ACCR3MCOLN3
SCHEMBL6303808 0.81 CRHBP (0.47) CRHBPCRHR2KMT2AALDH1A1MCOLN3
SCHEMBL6303803 0.81 CRHBP (0.47) CRHBPCRHR2KMT2AALDH1A1MCOLN3
SCHEMBL6306239 0.80 CRHBP (0.64) CRHBPCRHR2KMT2ALMNAALDH1A1
SCHEMBL6306235 0.80 CRHBP (0.64) CRHBPCRHR2KMT2ALMNAALDH1A1
SCHEMBL6311367 0.79 CRHBP (0.47) CRHBPCRHR2KMT2AALDH1A1MCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977265-B2 Piperidine CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2005-12-20 — — US disclosed
EP-1453825-A1 N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2004-09-08 — — EP disclosed
US-20030229121-A1 Piperidine CCR-3 receptor antagonists SYNTEX (U.S.A.) LLC 2003-12-11 — — US disclosed
WO-2003045937-A1 N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229121-A1 Piperidine CCR-3 receptor antagonists CCR1, CCR3, CCRL2 CRHBP 1470/4885CRHR2 185/4885KMT2A 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback